drugset / Trial / NCT01324063

A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)

NCT01324063

RandomizedTreatment

Summary

RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available

Timeline

Start
1986-11
Primary completion
1994-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytarabine Small molecule
Subject Daunorubicin Small molecule
Subject amsacrine Small molecule
Subject sargramostim Protein / enzyme biologic 5 ug/kg Intravenous

Indications